ASCENTAGE-B to Present Four Preclinical Studies at 2026 AACR Annual Meeting

Stock News03-18

ASCENTAGE-B (06855) announced that four of its preclinical research advancements have been selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place from April 17 to April 22, 2026, in San Diego, California, USA.

The data to be presented involve three of the company's drug candidates. These include the novel Class 1 BCR-ABL inhibitor olverembatinib (marketed as Nirlisq®; R&D code: HQP1351), the FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and the EED inhibitor APG-5918.

The AACR Annual Meeting serves as a critical platform for advancing oncology. It brings together scientists, clinicians, healthcare professionals, cancer survivors, patients, and advocates each year to share and discuss the latest breakthroughs in cancer research. The meeting comprehensively showcases cutting-edge science and medicine, covering areas from population science and prevention to cancer biology, translational and clinical research, and survivor care and advocacy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134901961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134901961","market":"hk","top_or_hot":-1,"title":"ASCENTAGE-B to Present Four Preclinical Studies at 2026 AACR Annual Meeting","media":"Stock News","content":"<p>ASCENTAGE-B (06855) announced that four of its preclinical research advancements have been selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place from April 17 to April 22, 2026, in San Diego, California, USA.</p>\n<p>The data to be presented involve three of the company's drug candidates. These include the novel Class 1 BCR-ABL inhibitor olverembatinib (marketed as Nirlisq®; R&D code: HQP1351), the FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and the EED inhibitor APG-5918.</p>\n<p>The AACR Annual Meeting serves as a critical platform for advancing oncology. It brings together scientists, clinicians, healthcare professionals, cancer survivors, patients, and advocates each year to share and discuss the latest breakthroughs in cancer research. The meeting comprehensively showcases cutting-edge science and medicine, covering areas from population science and prevention to cancer biology, translational and clinical research, and survivor care and advocacy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCENTAGE-B to Present Four Preclinical Studies at 2026 AACR Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCENTAGE-B to Present Four Preclinical Studies at 2026 AACR Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-18 08:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCENTAGE-B (06855) announced that four of its preclinical research advancements have been selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place from April 17 to April 22, 2026, in San Diego, California, USA.</p>\n<p>The data to be presented involve three of the company's drug candidates. These include the novel Class 1 BCR-ABL inhibitor olverembatinib (marketed as Nirlisq®; R&D code: HQP1351), the FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and the EED inhibitor APG-5918.</p>\n<p>The AACR Annual Meeting serves as a critical platform for advancing oncology. It brings together scientists, clinicians, healthcare professionals, cancer survivors, patients, and advocates each year to share and discuss the latest breakthroughs in cancer research. The meeting comprehensively showcases cutting-edge science and medicine, covering areas from population science and prevention to cancer biology, translational and clinical research, and survivor care and advocacy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1134901961","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134901961","pubTimestamp":1773793217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCENTAGE-B (06855) announced that four of its preclinical research advancements have been selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK4139":"生物科技","06855":"亚盛医药-B","AAPG":"亚盛医药","BK1161":"生物科技"},"translate_title":"ASCENTAGE-B将在2026年AACR年会上展示四项临床前研究","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAPG":1,"06855":1},"content_text":"ASCENTAGE-B (06855) announced that four of its preclinical research advancements have been selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place from April 17 to April 22, 2026, in San Diego, California, USA.\nThe data to be presented involve three of the company's drug candidates. These include the novel Class 1 BCR-ABL inhibitor olverembatinib (marketed as Nirlisq®; R&D code: HQP1351), the FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and the EED inhibitor APG-5918.\nThe AACR Annual Meeting serves as a critical platform for advancing oncology. It brings together scientists, clinicians, healthcare professionals, cancer survivors, patients, and advocates each year to share and discuss the latest breakthroughs in cancer research. The meeting comprehensively showcases cutting-edge science and medicine, covering areas from population science and prevention to cancer biology, translational and clinical research, and survivor care and advocacy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134901961","isCrawlerRequest":true}